Results 121 to 130 of about 172,168 (267)

Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum

open access: yesMedical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT We report the case of a 34‐year‐old male with persistent fever, ascites, thrombocytosis and clinical deterioration despite broad‐spectrum therapy who was ultimately diagnosed with peritoneal tuberculosis and concurrent chronic myeloid leukaemia.
Zayn Al‐Timimi   +3 more
wiley   +1 more source

Targeted disruption of the BCR-ABL fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells

open access: yesActa Biochimica et Biophysica Sinica
The BCR-ABL fusion gene, formed by the fusion of the breakpoint cluster region protein (BCR) and the Abl Oncogene 1, Receptor Tyrosine Kinase (ABL) genes, encodes the BCR-ABL oncoprotein, which plays a crucial role in leukemogenesis.
Zeng Jianling   +9 more
doaj   +1 more source

BCR-ABL downregulates PTEN expression.

open access: yes, 2014
A) Left panel: evaluation of PTEN levels of expression in BCR-ABL-pcDNA3.1 transfected NIH3T3. Right panel: quantification of PTEN levels. B) PTEN mRNA levels in BCR-ABL transfected NIH3T3 cells.
Sabrina Crivellaro (649162)   +5 more
core   +1 more source

Targeting USP10–FAK pathway sensitizes BCR-ABL+ leukemia cells to tyrosine kinase inhibitors

open access: yesCell Investigation
BCR-ABL+ leukemia is driven by constitutive tyrosine kinase activity, and tyrosine kinase inhibitors (TKIs) are the standard therapy. However, resistance to TKIs remains a significant clinical challenge.
Kangjie Qiu   +8 more
doaj   +1 more source

Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.

open access: yesPLoS ONE, 2015
Notch signalling is critical for haemopoietic stem cell (HSC) self-renewal and survival. The role of Notch signalling has been reported recently in chronic myeloid leukaemia (CML) - a stem cell disease characterized by BCR-ABL tyrosine kinase activation.
Abdullah Aljedai   +3 more
doaj   +1 more source

Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

open access: yes, 2008
Supplementary Fig. S2 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265)   +10 more
core   +1 more source

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance

open access: yesClinical Case Reports, 2018
Key Clinical Message I report a novel BCR‐ABL point mutation c.844G>C p.E282Q and a case of combination of two BCR‐ABL point mutations (p.E282Q and p.L298R) and exon 7 deletion (del. c.1086‐1270) in TKI‐resistant patient.
Ilya Mikhailov
doaj   +1 more source

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

open access: yes
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta   +3 more
wiley   +1 more source

Supplementary Fig. S5 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

open access: yes, 2008
Supplementary Fig. S5 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265)   +10 more
core   +1 more source

Supplementary Fig. S6 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

open access: yes, 2008
Supplementary Fig. S6 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265)   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy